Physician profile
Charles E Womack
NPI 1205810702
$9,740.42
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,573 · 2020: $1,104 · 2021: $1,694 · 2022: $2,254 · 2023: $1,116.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,116.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,092.15 | 2019-2023 | Xifaxan, Trulance |
| Astrazeneca Pharmaceuticals Lp | $991.69 | 2019-2023 | Breztri |
| Lilly USA, LLC | $673.22 | 2019-2023 | Jardiance, Mounjaro, Trulicity |
| Amgen INC. | $650.60 | 2019-2022 | |
| Glaxosmithkline, LLC. | $640.87 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Amarin Pharma, INC. | $558.50 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $444.64 | 2019-2023 | |
| Abbvie INC. | $437.98 | 2019-2023 | Qulipta |
| Merck Sharp & Dohme LLC | $385.71 | 2019-2023 | Steglatro, Belsomra, Lagevrio |
| Novo Nordisk INC | $349.45 | 2019-2023 | Ozempic, Rybelsus, Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $342.66 | 2021-2023 | |
| Pfizer INC. | $338.69 | 2019-2023 | |
| Abbott Laboratories | $297.78 | 2019-2023 | Freestyle Libre 3 |
| Allergan, INC. | $269.64 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $264.20 | 2019-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Womack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.